Effect of High Dose Intravenous Vitamin C in Severe Pneumonia

Exclusion Criteria21

• Known allergy to Vitamin C
• Pregnancy
• Known history of ongoing concomitant infection
• Participation in another clinical trial and/or receipt of investigational drugs within 4 weeks prior to enrollment
• Moribund patient with multiorgan failure to the judgement of the treating physician, who is not expected to survive 24 hours
• Patient who requires home oxygen therapy or mechanical ventilation, including tracheostomy or non-invasive ventilation, except for CPAP/BIPAP for sleep-disordered breathing
• Known history of previous or current diagnosis of renal stones
• Known diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency
• Known diagnosis of hemochromatosis
• Known diagnosis of poorly controlled chronic pulmonary disease, including:
• Chronic obstructive pulmonary disease with oxygen therapy
• Chronic restrictive pulmonary disease with oxygen therapy
• Bronchial asthma on Step 5 of treatment ladder as shown in Pocket Guide for Asthma Management and Prevention
• Lung cancer in Stage IV of disease
• Known diagnosis of heart failure on anti-failure treatment or requiring mechanical hemodynamic support (e.g. LVAD), with recent hospitalization within 3 months (90 days) from the date of current admission.
• Immunocompromised state
• Known diagnosis of malignancy and ongoing chemotherapy or radiotherapy as there is evidence that antioxidant supplement before and during treatment was associated with an increased hazard of recurrence
• Known diagnosis of malignancy who had completed chemotherapy or radiotherapy with absolute neutrophil count ≤100 cells/mm3
• Known diagnosis of Stage 4 and above chronic kidney disease (GFR <30 ml/min/1.73m2) and end-stage renal disease on regular dialysis (including peritoneal dialysis or hemodialysis)
• Known history of renal transplantation
• Absence of family members or next of kin for informed consent